Tracy Robson

Tracy Robson

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
Helen McCarthyHelen McCarthy
Helen McCarthy
JMJoanne McCaffrey
Joanne McCaffrey
CMCian M. McCrudden
Cian M. McCrudden
AZAleksey Zholobenko
Aleksey Zholobenko
AAAhlam A. Ali
Ahlam A. Ali
TRTracy Robson
Tracy Robson

1 November 1996 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
MJM.C. Joiner
M.C. Joiner
Philippe LambinPhilippe Lambin
Philippe Lambin
EME.P. Malaise
E.P. Malaise
TRTracy Robson
Tracy Robson
JAJ.E. Arrand
J.E. Arrand
BMB. Marples
B. Marples

5 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
Jennifer DowlingJennifer Dowling
Jennifer Dowling
Remsha AfzalRemsha Afzal
Remsha Afzal
LGLinden J. Gearing
Linden J. Gearing
MCMariana P. Cervantes-Silva
Mariana P. Cervantes-Silva
SAStephanie Annett
Stephanie Annett
CMClaire McCoy
Claire McCoy
Mitochondria are important regulators of macrophage polarisation. Here, we show that arginase-2 (Arg2) is a microRNA-155 (miR-155) and interleukin-10 (IL-10) regulated protein localized at the mitochondria in inflammatory macrophages, and is critical for IL-10-induced modulation of mitochondrial dynamics and oxidative respiration. Mechanistically, the catalytic activity and presence of Arg2 at the mitochondria is crucial for oxidative phosphorylation. We further show that Arg2 mediates this process by increasing the activity of complex II (succinate dehydrogenase). Moreover, Arg2 is essential for IL-10-mediated downregulation of the inflammatory mediators succinate, hypoxia inducible factor 1α (HIF-1α) and IL-1β in vitro. Accordingly, HIF-1α and IL-1β are highly expressed in an LPS-induced in vivo model of acute inflammation using Arg2−/− mice. These findings shed light on a new arm of IL-10-mediated metabolic regulation, working to resolve the inflammatory status of the cell.

20 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
GMGillian Moore
Gillian Moore
SAStephanie L. Annett
Stephanie L. Annett
LMLana McClements
Lana McClements
TRTracy Robson
Tracy Robson
Evolutionarily conserved Notch plays a critical role in embryonic development and cellular self-renewal. It has both tumour suppressor and oncogenic activity, the latter of which is widely described. Notch-activating mutations are associated with haematological malignancies and several solid tumours including breast, lung and adenoid cystic carcinoma. Moreover, upregulation of Notch receptors and ligands and aberrant Notch signalling is frequently observed in cancer. It is involved in cancer hallmarks including proliferation, survival, migration, angiogenesis, cancer stem cell renewal, metastasis and drug resistance. It is a key component of cell-to-cell interactions between cancer cells and cells of the tumour microenvironment, such as endothelial cells, immune cells and fibroblasts. Notch displays diverse crosstalk with many other oncogenic signalling pathways, and may drive acquired resistance to targeted therapies as well as resistance to standard chemo/radiation therapy. The past 10 years have seen the emergence of different classes of drugs therapeutically targeting Notch including receptor/ligand antibodies, gamma secretase inhibitors (GSI) and most recently, the development of Notch transcription complex inhibitors. It is an exciting time for Notch research with over 70 cancer clinical trials registered and the first-ever Phase III trial of a Notch GSI, nirogacestat, currently at the recruitment stage.

1 April 2017 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Open access
AAAhlam A. Ali
Ahlam A. Ali
CMCian M. McCrudden
Cian M. McCrudden
JMJoanne McCaffrey
Joanne McCaffrey
JMJohn W. McBride
John W. McBride
GCGrace Cole
Grace Cole
Helen McCarthyHelen McCarthy
Helen McCarthy
HPV subtypes (16, 18) are associated with the development of cervical cancer, with oncoproteins E6 and E7 responsible for pathogenesis. The goal of this study was to evaluate our 'smart system' technology platform for DNA vaccination against cervical cancer. The vaccination platform brings together two main components; a peptide RALA which condenses DNA into cationic nanoparticles (NPs), and a polymeric polyvinylpyrrolidone (PVP) microneedle (MN) patch for cutaneous delivery of the loaded NPs. RALA condensed E6/E7 DNA into NPs not exceeding 100nm in diameter, and afforded the DNA protection from degradation in PVP. Sera from mice vaccinated with MN/RALA-E6/E7 were richer in E6/E7-specific IgGs, displayed a greater T-cell-mediated TC-1 cytotoxicity and contained more IFN-γ than sera from mice that received NPs intramuscularly. More importantly, MN/RALA-E6/E7 delayed TC-1 tumor initiation in a prophylactic model, and slowed tumor growth in a therapeutic model of vaccination, and was more potent than intramuscular vaccination.

1 November 2020 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SAStephanie Annett
Stephanie Annett
GMGillian Moore
Gillian Moore
TRTracy Robson
Tracy Robson